Stoke Therapeutics, Inc.(STOK)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Stoke Therapeutics, Inc. (STOK) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STOK at 24.9/100 on a 32-signal composite quality model, placing it at rank #2,681 of 2,962 stocks — the bottom half of the AI-ranked universe. STOK scores in the top quartile across revenue growth (95.3). Areas of concern include free cash flow (2.3) and profitability (2.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Stoke Therapeutics, Inc. reports quarterly revenue of $9.3M, net income of $-61.6M, free cash flow of $-58.6M. Top institutional holders of STOK by reported 13-F value include BlackRock, RTW INVESTMENTS, FMR, based on the most recent SEC filings. STOK trades on the Nasdaq exchange and files with the SEC under CIK 1623526. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STOK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Stoke Therapeutics, Inc. directly from SEC EDGAR.